Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs
Author:
Publisher
Springer Paris
Link
http://link.springer.com/content/pdf/10.1007/978-2-8178-0245-9_33.pdf
Reference170 articles.
1. Andre F, Campone M, O’Regan R et al. (2010) Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. J Clin Oncol 28: 5110–5115
2. Andreopoulou E, Gaiotti D, Kim E et al. (2007) Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clinical breast cancer 7: 690–696
3. Arnould L, Gelly M, Penault-Llorca F et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267
4. Awada A, Dirix L, Beck J et al. (2009) Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US
5. Bartsch R, Wenzel C, Altorjai G et al. (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25: 3853–3858
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3